Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct 1;3(10):a015669.
doi: 10.1101/cshperspect.a015669.

Opportunistic infections--coming to the limits of immunosuppression?

Affiliations
Review

Opportunistic infections--coming to the limits of immunosuppression?

Jay A Fishman. Cold Spring Harb Perspect Med. .

Abstract

Possible etiologies of infection in the solid organ recipient are diverse, ranging from common bacterial and viral pathogens to opportunistic pathogens that cause invasive disease only in immunocompromised hosts. The recognition of infectious syndromes in this population is limited by alterations in the clinical manifestations by immunosuppression. The risk of serious infections in the organ transplant patient is determined by the interaction between the patients' recent and distant epidemiological exposures and all factors that contribute to the patient's net state of immune suppression. This risk is altered by antimicrobial prophylaxis and changes in immunosuppressive therapies. In addition to the direct effects of infection, opportunistic infections, and the microbiome may adversely shape the host immune responses with diminished graft and patient survivals. Antimicrobial therapies are more complex than in the normal host with a significant incidence of drug toxicity and a propensity for drug interactions with the immunosuppressive agents used to maintain graft function. Rapid and specific microbiologic diagnosis is essential. Newer microbiologic assays have improved the diagnosis and management of opportunistic infections. These tools coupled with assays that assess immune responses to infection and to graft antigens may allow optimization of management for graft recipients in the future.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The timeline of infections following organ transplantation. The risk for infection following organ transplantation follows a standard pattern with routine immunosuppression and infectious exposures. The potential pathogens for which the risk is modified by prophylaxis, including vaccinations and antimicrobial agents, are indicated (*). Individual risk is modified by events such as surgery, treatment of graft rejection, or malignancy. Note that graft rejection and drug reactions may be among noninfectious causes of fever in transplant recipients. (From Fishman 2007; modified, with permission, from the author.)
Figure 2.
Figure 2.
The impact of infectious exposures, inflammation, the microbiome, heterologous immunity, and innate immune stimulation on transplantation. The microbiome is the sum of colonizing organisms, acute and chronic infections, and reflects alterations in this flora by the immune system, vaccination, or antimicrobial agents. Antigens and activating molecular patterns from microbes or damaged tissues are released during all phases of transplantation and are present during graft rejection, immunosuppression, and/or immune reconstitution following lymphocyte depletion. These antigenic exposures and inflammatory mediators shape immune function via both the innate and adaptive immune systems and impact the outcome of transplantation (see also Chong and Alegre 2012).

References

    1. Adams AB, Pearson TC, Larsen CP 2003a. Heterologous immunity: An overlooked barrier to tolerance. Immunol Rev 196: 147–160 - PubMed
    1. Adams AB, Williams MA, Jones TR, Shirasugi N, Durham MM, Kaech SM, Wherry EJ, Onami T, Lanier JG, Kokko KE, et al. 2003b. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 111: 1887–1895 - PMC - PubMed
    1. Avery RK 2006. Infections after lung transplantation. Semin Respir Crit Care Med 27: 544–551 - PubMed
    1. Bando K, Paradis IL, Komatsu K, Konishi H, Matsushima M, Keena RJ, Hardesty RL, Armitage JM, Griffith BP 1995. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg 109: 49–57; discussion 57-49 - PubMed
    1. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, et al. 2003. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 43: 788–798 - PubMed

MeSH terms

Substances

LinkOut - more resources